Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that Tanshinone IIA mediates SMAD7-YAP interaction to induce liver cancer cell apoptosis and inhibit cell growth and migration by inactivating the transforming growth factor beta (TGF-β) signaling pathway.
|
31711043 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice.
|
31754005 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased miR-424-5p expression and increased YAP1 expression are found in patients with liver cancer.
|
30676784 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of YAP1 showed great association with poorer prognosis in patients with various cancers, particularly liver cancer.
|
31613226 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
We and others have demonstrated that the genetic disruption of kinases Mst1 and Mst2 (Mst1/2), the core components of Hippo signaling, results in YAP activation and sustained liver growth, thereby leading to an eight- to tenfold increase in liver size within 3 months and occurrence of liver cancer within 5 months (Curr Biol 17(23):2054-2060, 2007; Cancer Cell 16(5):425-438, 2009; Cell 130(6):1120-1133, 2007; Cancer Cell 31(5):669-684 e667, 2017; Nat Commun 6:6239, 2015; Cell Rep 3(5):1663-1677, 2013).
|
30565146 |
2019 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer.
|
31428581 |
2019 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings suggest that YAP1, highly expressed in malignant liver tumours, contributes to hepatocellular CSCs phenotype and is a molecular target of interest for CSCs targeted therapy in liver cancer patients.
|
29698666 |
2018 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
NUAK2 is a critical YAP target in liver cancer.
|
30446657 |
2018 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we find a strong correlation between YOD1 and YAP expression in liver cancer patients.
|
28416659 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hippo pathway leads to phosphorylation of the transcriptional activator yes-associated protein 1 (YAP1, YAP), which regulates proliferation and has been associated with the development of liver cancer.
|
28249813 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, Scrib inhibits liver cancer cell proliferation by suppressing the expression of three oncogenes, Yap1, c-Myc and cyclin D1, thereby functioning as a tumor suppressor in liver cancer.
|
28460446 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a strong correlation was observed between YOD1 and YAP expression in liver cancer patients.
|
28502290 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, human liver cancer tissue microarray (TMA) shown YAP1 expression was closely to clinic.
|
29187885 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of LATS1 and the nucleocytoplasmic translocation of YAP1 play an anti-oncogenetic role in the occurrence and development of liver cancer.
|
28076850 |
2017 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We further show that Agrin promotes oncogenesis through YAP-dependent transcription and is clinically relevant in human liver cancer.
|
28273460 |
2017 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recently discovered positive feedback loop between activated YAP1 and increased EGFR/KRAS signalling found in oesophageal, ovarian and hepatocellular cancer has been related to the CRC progression and resistance to EGFR inhibitors during CRC therapy.
|
26160682 |
2015 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We used immunohistochemical analysis to determine expression of β-catenin and Yap1 in liver cancer specimens collected from patients in Europe and the United States, consisting of 104 hepatocellular carcinoma, 62 intrahepatic cholangiocarcinoma, and 94 hepatoblastoma samples.
|
24837480 |
2014 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previously study demonstrated that CD166 exerts its anti-apoptotic role through interaction with YAP in liver cancer.
|
25094049 |
2014 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our study uncovers a regulatory mechanism underlying liver cancer-specific Wnt transcriptional output, and suggests that TRIB2 functions as a signaling nexus to integrate the Wnt/β-catenin, Hippo/YAP, and C/EBPα pathways in cancer cells.
|
23769673 |
2013 |
Malignant neoplasm of liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using ChIP-on-chip screens and ChIP assays, we find that menin occupancy frequently coincides with H3K4me3 at the promoter of many liver cancer-related genes, such as Yes-associated protein (Yap1).
|
24101467 |
2013 |
Malignant neoplasm of liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to measure YAP gene expression and protein levels during rat liver regeneration and in liver cancer, and to explore possible correlations between YAP levels and cancer cell proliferation following partial hepatectomy.
|
22012126 |
2012 |